The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes

[1]  J. Castilla,et al.  De novo induction of amyloid-β deposition in vivo , 2013, Molecular Psychiatry.

[2]  J. Castilla,et al.  De novo induction of amyloid-β deposition in vivo , 2012, Molecular Psychiatry.

[3]  K. Ashe,et al.  Cognitive effects of cell-derived and synthetically derived Aβ oligomers , 2011, Neurobiology of Aging.

[4]  M. Rowan,et al.  A monoclonal antibody against synthetic Aβ dimer assemblies neutralizes brain‐derived synaptic plasticity‐disrupting Aβ , 2011, Journal of neurochemistry.

[5]  B. Strooper,et al.  The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics , 2011, Nature Reviews Drug Discovery.

[6]  C. Dobson,et al.  Stabilization of neurotoxic Alzheimer amyloid-beta oligomers by protein engineering , 2011, Alzheimer's & Dementia.

[7]  David M Holtzman,et al.  Human apoE Isoforms Differentially Regulate Brain Amyloid-β Peptide Clearance , 2011, Science Translational Medicine.

[8]  J. Kelly,et al.  Amyloid-β Forms Fibrils by Nucleated Conformational Conversion of Oligomers , 2011, Nature chemical biology.

[9]  M. Hoch,et al.  Extracellular phosphorylation of the amyloid β‐peptide promotes formation of toxic aggregates during the pathogenesis of Alzheimer's disease , 2011, The EMBO journal.

[10]  E. Goormaghtigh,et al.  High ability of apolipoprotein E4 to stabilize amyloid‐β peptide oligomers, the pathological entities responsible for Alzheimer's disease , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[11]  G. Collingridge,et al.  Aβ1–42 inhibition of LTP is mediated by a signaling pathway involving caspase-3, Akt1 and GSK-3β , 2011, Nature Neuroscience.

[12]  R. Kayed,et al.  Amyloid-β Annular Protofibrils Evade Fibrillar Fate in Alzheimer Disease Brain*♦ , 2011, The Journal of Biological Chemistry.

[13]  D. Eisenberg,et al.  Characteristics of amyloid-related oligomers revealed by crystal structures of macrocyclic β-sheet mimics. , 2011, Journal of the American Chemical Society.

[14]  D. Selkoe,et al.  Soluble amyloid β-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration , 2011, Proceedings of the National Academy of Sciences.

[15]  Shinichiro Nakamura,et al.  Two Distinct Amyloid β-Protein (Aβ) Assembly Pathways Leading to Oligomers and Fibrils Identified by Combined Fluorescence Correlation Spectroscopy, Morphology, and Toxicity Analyses* , 2011, The Journal of Biological Chemistry.

[16]  Julie R. Leitz,et al.  Tau Protein Is Required for Amyloid β-Induced Impairment of Hippocampal Long-Term Potentiation , 2011, The Journal of Neuroscience.

[17]  T. Wyttenbach,et al.  Ion mobility-mass spectrometry reveals a conformational conversion from random assembly to beta-sheet in amyloid fibril formation , 2010, Nature chemistry.

[18]  Frank Baumann,et al.  Peripherally Applied Aβ-Containing Inoculates Induce Cerebral β-Amyloidosis , 2010, Science.

[19]  N. Ferguson,et al.  Amyloid β-Protein Dimers Rapidly Form Stable Synaptotoxic Protofibrils , 2010, The Journal of Neuroscience.

[20]  Inna Kuperstein,et al.  Neurotoxicity of Alzheimer's disease Aβ peptides is induced by small changes in the Aβ42 to Aβ40 ratio , 2010, The EMBO journal.

[21]  E. Mandelkow,et al.  Aβ Oligomers Cause Localized Ca2+ Elevation, Missorting of Endogenous Tau into Dendrites, Tau Phosphorylation, and Destruction of Microtubules and Spines , 2010, The Journal of Neuroscience.

[22]  C. Dobson,et al.  Stabilization of neurotoxic Alzheimer amyloid-β oligomers by protein engineering , 2010, Proceedings of the National Academy of Sciences.

[23]  Jürgen Götz,et al.  Dendritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer's Disease Mouse Models , 2010, Cell.

[24]  H. Schoemaker,et al.  Generation and Therapeutic Efficacy of Highly Oligomer-Specific β-Amyloid Antibodies , 2010, The Journal of Neuroscience.

[25]  C. Rowe,et al.  Blood-Borne Amyloid-β Dimer Correlates with Clinical Markers of Alzheimer's Disease , 2010, The Journal of Neuroscience.

[26]  D. Selkoe,et al.  The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia. , 2010, Brain : a journal of neurology.

[27]  B. Strooper.  Proteases and Proteolysis in Alzheimer Disease: A Multifactorial View on the Disease Process , 2010 .

[28]  Tara Spires-Jones,et al.  Amyloid β Induces the Morphological Neurodegenerative Triad of Spine Loss, Dendritic Simplification, and Neuritic Dystrophies through Calcineurin Activation , 2010, The Journal of Neuroscience.

[29]  Xiongwei Zhu,et al.  Amyloid-β-Derived Diffusible Ligands Cause Impaired Axonal Transport of Mitochondria in Neurons , 2010, Neurodegenerative Diseases.

[30]  Fabrizio Chiti,et al.  A causative link between the structure of aberrant protein oligomers and their toxicity. , 2010, Nature chemical biology.

[31]  E. Chen-Dodson,et al.  Anti-ADDL antibodies differentially block oligomer binding to hippocampal neurons , 2010, Neurobiology of Aging.

[32]  K. Blennow,et al.  Distinct cerebrospinal fluid amyloid β peptide signatures in sporadic and PSEN1 A431E-associated familial Alzheimer's disease , 2010, Molecular Neurodegeneration.

[33]  Jin-Moo Lee,et al.  Amyloid seeds formed by cellular uptake, concentration, and aggregation of the amyloid-beta peptide , 2009, Proceedings of the National Academy of Sciences.

[34]  L. Lannfelt,et al.  An amyloid-β protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer's disease , 2009, Neurobiology of Disease.

[35]  D. Selkoe,et al.  Biochemical and immunohistochemical analysis of an Alzheimer's disease mouse model reveals the presence of multiple cerebral Aβ assembly forms throughout life , 2009, Neurobiology of Disease.

[36]  B. de Strooper,et al.  G Protein–Coupled Receptors, Cholinergic Dysfunction, and Aβ Toxicity in Alzheimer’s Disease , 2009, Science Signaling.

[37]  A. Fagan,et al.  Multimodal techniques for diagnosis and prognosis of Alzheimer's disease , 2009, Nature.

[38]  Adriano Aguzzi,et al.  Prions: protein aggregation and infectious diseases. , 2009, Physiological reviews.

[39]  M. Luca,et al.  Faculty Opinions recommendation of Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. , 2009 .

[40]  K. Imahori,et al.  Isolation and Characterization of Patient-derived, Toxic, High Mass Amyloid β-Protein (Aβ) Assembly from Alzheimer Disease Brains* , 2009, The Journal of Biological Chemistry.

[41]  D. Teplow,et al.  Structure-neurotoxicity relationships of amyloid β-protein oligomers , 2009, Neuroscience Research.

[42]  John Hardy,et al.  The amyloid hypothesis for Alzheimer’s disease: a critical reappraisal , 2009, Journal of neurochemistry.

[43]  Hans-Ulrich Demuth,et al.  Pyroglutamate formation influences solubility and amyloidogenicity of amyloid peptides. , 2009, Biochemistry.

[44]  Shaomin Li,et al.  Soluble Oligomers of Amyloid β Protein Facilitate Hippocampal Long-Term Depression by Disrupting Neuronal Glutamate Uptake , 2009, Neuron.

[45]  Ghiam Yamin.  NMDA receptor–dependent signaling pathways that underlie amyloid β‐protein disruption of LTP in the hippocampus , 2009, Journal of neuroscience research.

[46]  G. Zamponi.  Faculty Opinions recommendation of Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. , 2009 .

[47]  A. Cattaneo,et al.  Direct in vivo intracellular selection of conformation-sensitive antibody domains targeting Alzheimer's amyloid-beta oligomers. , 2009, Journal of molecular biology.

[48]  I. Bezprozvanny.  Amyloid Goes Global , 2009, Science Signaling.

[49]  John W. Gilbert,et al.  Cellular Prion Protein Mediates Impairment of Synaptic Plasticity by Amyloid-β Oligomers , 2009, Nature.

[50]  C. Duyckaerts,et al.  Single-domain antibodies recognize selectively small oligomeric forms of amyloid beta, prevent Abeta-induced neurotoxicity and inhibit fibril formation. , 2009, Molecular immunology.

[51]  S. Love,et al.  Characterisation of two antibodies to oligomeric Aβ and their use in ELISAs on human brain tissue homogenates , 2009, Journal of Neuroscience Methods.

[52]  M. Sierks,et al.  Anti-oligomeric Abeta single-chain variable domain antibody blocks Abeta-induced toxicity against human neuroblastoma cells. , 2008, Journal of molecular biology.

[53]  H. Fukuyama,et al.  Peripheral Aβ subspecies as risk biomarkers of Alzheimer's disease , 2008, Proceedings of the National Academy of Sciences.

[54]  E. Bigio,et al.  Alzheimer's disease-type neuronal tau hyperphosphorylation induced by Aβ oligomers , 2008, Neurobiology of Aging.

[55]  Shaomin Li,et al.  Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory , 2008, Nature Medicine.

[56]  Shaomin Li,et al.  Transglutaminase Induces Protofibril-like Amyloid β-Protein Assemblies That Are Protease-resistant and Inhibit Long-term Potentiation* , 2008, Journal of Biological Chemistry.

[57]  Yasuyoshi Watanabe,et al.  A new amyloid β variant favoring oligomerization in Alzheimer's‐type dementia , 2008, Annals of neurology.

[58]  C. Sachse,et al.  Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing Aβ protofibrils , 2007, Proceedings of the National Academy of Sciences.

[59]  John Collinge,et al.  A General Model of Prion Strains and Their Pathogenicity , 2007, Science.

[60]  R. Rich,et al.  Molecular basis for passive immunotherapy of Alzheimer's disease , 2007, Proceedings of the National Academy of Sciences.

[61]  Dag Sehlin,et al.  Sensitive ELISA detection of amyloid‐β protofibrils in biological samples , 2007 .

[62]  Elizabeth Head,et al.  Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers , 2007, Molecular Neurodegeneration.

[63]  R. Ferrante,et al.  Conformation-sensitive Antibodies against Alzheimer Amyloid-β by Immunization with a Thioredoxin-constrained B-cell Epitope Peptide* , 2007, Journal of Biological Chemistry.

[64]  R. J. Kelleher,et al.  The presenilin hypothesis of Alzheimer's disease: Evidence for a loss-of-function pathogenic mechanism , 2007, Proceedings of the National Academy of Sciences.

[65]  E. Bigio,et al.  Monoclonal antibodies that target pathological assemblies of Aβ , 2007, Journal of neurochemistry.

[66]  R. Hepler,et al.  Solution State Characterization of Amyloid β-Derived Diffusible Ligands , 2006 .

[67]  D. Walsh,et al.  Exogenous Induction of Cerebral ß-Amyloidogenesis Is Governed by Agent and Host , 2006, Science.

[68]  C. Masters,et al.  Copper-mediated Amyloid-β Toxicity Is Associated with an Intermolecular Histidine Bridge* , 2006, Journal of Biological Chemistry.

[69]  J. Busciglio,et al.  Different Conformations of Amyloid β Induce Neurotoxicity by Distinct Mechanisms in Human Cortical Neurons , 2006, The Journal of Neuroscience.

[70]  D. Selkoe,et al.  Effects of secreted oligomers of amyloid β‐protein on hippocampal synaptic plasticity: a potent role for trimers , 2006, The Journal of physiology.

[71]  M. Gallagher,et al.  A specific amyloid-β protein assembly in the brain impairs memory , 2006, Nature.

[72]  G. Bitan,et al.  Amyloid β‐protein monomer structure: A computational and experimental study , 2006, Protein science : a publication of the Protein Society.

[73]  C. Ross,et al.  What is the role of protein aggregation in neurodegeneration? , 2005, Nature Reviews Molecular Cell Biology.

[74]  P. Keller,et al.  Globular amyloid β‐peptide1−42 oligomer − a homogenous and stable neuropathological protein in Alzheimer's disease , 2005 .

[75]  G. Bitan,et al.  Neurotoxic protein oligomers — what you see is not always what you get , 2005, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[76]  Ian Parker,et al.  Calcium Dysregulation and Membrane Disruption as a Ubiquitous Neurotoxic Mechanism of Soluble Amyloid Oligomers*♦ , 2005, Journal of Biological Chemistry.

[77]  R. Rydel,et al.  Nucleation-Dependent Polymerization Is an Essential Component of Amyloid-Mediated Neuronal Cell Death , 2005, The Journal of Neuroscience.

[78]  Richard D. Leapman,et al.  Self-Propagating, Molecular-Level Polymorphism in Alzheimer's ß-Amyloid Fibrils , 2005, Science.

[79]  P. Lansbury,et al.  Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. , 2003, Annual review of neuroscience.

[80]  P. Maher,et al.  The Regulation of Glucose Metabolism by HIF-1 Mediates a Neuroprotective Response to Amyloid Beta Peptide , 2003, Neuron.

[81]  Kazuki Sato,et al.  Spherical aggregates of β-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3β , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[82]  Carl W. Cotman,et al.  Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis , 2003, Science.

[83]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[84]  W. K. Cullen,et al.  Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.

[85]  R. Wetzel,et al.  Conformational Abs recognizing a generic amyloid fibril epitope , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[86]  T. Morgan,et al.  Vaccination with soluble Aβ oligomers generates toxicity‐neutralizing antibodies , 2001, Journal of neurochemistry.

[87]  N. Danbolt.  Glutamate uptake , 2001, Progress in Neurobiology.

[88]  S. Younkin,et al.  The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Aβ protofibril formation , 2001, Nature Neuroscience.

[89]  J. David Sweatt,et al.  β-Amyloid Activates the Mitogen-Activated Protein Kinase Cascade via Hippocampal α7 Nicotinic Acetylcholine Receptors:In Vitro and In Vivo Mechanisms Related to Alzheimer's Disease , 2001, The Journal of Neuroscience.

[90]  C. Masters,et al.  Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease , 1999, Annals of neurology.

[91]  T. Morgan,et al.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[92]  D. Walsh,et al.  Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate. , 1997, The Journal of biological chemistry.

[93]  D. Selkoe,et al.  Enhanced Production and Oligomerization of the 42-residue Amyloid β-Protein by Chinese Hamster Ovary Cells Stably Expressing Mutant Presenilins* , 1997, The Journal of Biological Chemistry.

[94]  M. Emmerling,et al.  Morphology and Toxicity of Aβ-(1-42) Dimer Derived from Neuritic and Vascular Amyloid Deposits of Alzheimer's Disease* , 1996, The Journal of Biological Chemistry.

[95]  Steven A. Johnson,et al.  Clusterin (apoJ) Alters the Aggregation of Amyloid β-Peptide (Aβ1-42) and Forms Slowly Sedimenting Aβ Complexes That Cause Oxidative Stress , 1995, Experimental Neurology.

[96]  S. Squazzo,et al.  Aggregation of Secreted Amyloid -Protein into Sodium Dodecyl Sulfate-stable Oligomers in Cell Culture (*) , 1995, The Journal of Biological Chemistry.

[97]  T. Crow,et al.  Induction of beta (A4)-amyloid in primates by injection of Alzheimer's disease brain homogenate. Comparison with transmission of spongiform encephalopathy. , 1994, Molecular neurobiology.

[98]  P. Lansbury,et al.  The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. , 1993, Biochemistry.

[99]  Carl W. Cotman,et al.  In vitro aging of ß-amyloid protein causes peptide aggregation and neurotoxicity , 1991, Brain Research.

[100]  State of aggregation , 2011, Nature Neuroscience.

[101]  R. Panush.  Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis , 2011 .

[102]  Brian E. Keck.  A Critical Reappraisal , 2010 .

[103]  B. de Strooper.  Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process. , 2010, Physiological reviews.

[104]  F. Nicoletti,et al.  The Monomer State of Beta-Amyloid: Where the Alzheimer's Disease Protein Meets Physiology , 2010, Reviews in the neurosciences.

[105]  E. Bigio,et al.  Alzheimer's disease-type neuronal tau hyperphosphorylation induced by A beta oligomers. , 2008, Neurobiology of aging.

[106]  L. Lannfelt,et al.  Sensitive ELISA detection of amyloid-beta protofibrils in biological samples. , 2007, Journal of neurochemistry.

[107]  Michela Gallagher,et al.  A specific amyloid-beta protein assembly in the brain impairs memory. , 2006, Nature.

[108]  R. Hepler,et al.  Solution state characterization of amyloid beta-derived diffusible ligands. , 2006, Biochemistry.

[109]  G. Bitan,et al.  Amyloid beta-protein monomer structure: a computational and experimental study. , 2006, Protein science : a publication of the Protein Society.

[110]  J. Trojanowski,et al.  Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice. , 2006, The Journal of biological chemistry.

[111]  D. Selkoe,et al.  Natural oligomers of the amyloid-β protein specifically disrupt cognitive function , 2005, Nature Neuroscience.

[112]  P. Keller,et al.  Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease. , 2005, Journal of neurochemistry.

[113]  Kazuki Sato,et al.  Spherical aggregates of beta-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3beta. , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[114]  J. Sweatt,et al.  Beta-amyloid activates the mitogen-activated protein kinase cascade via hippocampal alpha7 nicotinic acetylcholine receptors: In vitro and in vivo mechanisms related to Alzheimer's disease. , 2001, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[115]  C. Franceschi,et al.  In vitro peroxidase oxidation induces stable dimers of beta-amyloid (1-42) through dityrosine bridge formation. , 1999, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[116]  P. Lansbury,et al.  Observation of metastable Abeta amyloid protofibrils by atomic force microscopy. , 1997, Chemistry & biology.

[117]  Peter T. Lansbury,et al.  Observation of metastable Aβ amyloid protofibrils by atomic force microscopy , 1997 .

[118]  W. B. Stine,et al.  Clusterin (apoJ) alters the aggregation of amyloid beta-peptide (A beta 1-42) and forms slowly sedimenting A beta complexes that cause oxidative stress. , 1995, Experimental neurology.

[119]  C. Cotman,et al.  In vitro aging of beta-amyloid protein causes peptide aggregation and neurotoxicity. , 1991, Brain research.